Walczak J. , Pawlik D. , Jasińska A. , Garbacka M ... J. , Pawlik D. , Jasińska A. , Garbacka M.....
1
Mean change in HbA_1c [%] -0,37% -0,42% -1,53% -0,22% -0,42% -1,67% -2,00% -1,00% 0,00% type 1 type 2 basal-bolus type 2 insulin+OAD IDet NPH Mean change in BMI [kg/m2] -0,2 0,26 0,42 0,06 0,51 0,99 type 1 type 2 basal- bolus type 2 insulin+OAD IDet NPH Non-specific mortality No Yes No Yes Laser treatment ACEI treatment Statin treatment Aspirin treatment User sets simulation conditions Generate baseline population Any patients to run? Time horizon reached? Stop Screening Overall annual survival Time counter advances Update simulation data ACEI – Angiotensin converting enzyme inhibitor Microvascular complications Macrovascular complications Walczak J. , Pawlik D. , Jasińska A. , Garbacka M.. , Kędzior J. , Fundament T. , Malczak I. , Dardziński W. , Nogas G. , Skrzekowska-Baran I. , Czech M. Arcana Institute, Cracow, Poland, Novo Nordisk Pharma Poland, Warsaw, Poland 1 1 1 1 1 1 1 1 1 2 2 1 2 Insulin detemir Packet Public selling price (VAT included) [PLN] Reimbursement [PLN] Patient’s co- payment [PLN] Reimbursement per 1 i.u. [PLN] Levemir 5 wkl. 3ml 271,01 267,81 3,20 0,18 Type 1 and type 2 diabetes patients treated with IIT Proportion of patients with episodes of severe hypoglycaemia * Proportion of patients treated with IIT, receiving NPH insulin Target population 65 800 0,089 95% 65 800 × 95% × 8,9% = about 5,6 thousand patients Total annual cost [PLN] IDet NPH Type 1 diabetes Insulin detemir/NPH 1 903,74 792,82 Short-/ rapid-acting insulin 828,42 592,85 Total 2 732,16 1 385,67 Type 2 diabetes (intensive insulin therapy) Insulin detemir/NPH 2 662,87 1 005,92 Total 3 988,56 1 788,05 Type 2 diabetes (insulin + oral antidiabetes drugs) Insulin detemir/NPH 3 303,17 1 114,11 Oral antidiabetes drugs 327,38 327,38 Total 3 630,55 1 441,49
Transcript of Walczak J. , Pawlik D. , Jasińska A. , Garbacka M ... J. , Pawlik D. , Jasińska A. , Garbacka M.....
Mean change in HbA_1c [%]
-0,37%
-0,42%
-1,53%
-0,22%
-0,42%
-1,67%
-2,00% -1,00% 0,00%
type 1
type 2 basal-bolus
type 2 insulin+OAD
IDet NPH
Mean change in BMI [kg/m2]
-0,2
0,26
0,42
0,06
0,51
0,99
type 1
type 2 basal-
bolus
type 2
insulin+OAD
IDet NPH
Non-specificmortality
No
Yes
No
Yes
Lasertreatment
ACEI
treatment
Statin
treatment
Aspirin
treatment
User sets simulation conditions
Generate baseline population
Any patients to run?
Time horizon reached?
Stop
Screening
Overall annual survival
Time counter advances
Update simulation data
ACEI – Angiotensin converting enzyme inhibitor
Microvascularcomplications
Macrovascularcomplications
Walczak J. , Pawlik D. , Jasińska A. , Garbacka M.. , Kędzior J. , Fundament T. , Malczak I. , Dardziński W. , Nogas G. , Skrzekowska-Baran I. , Czech M.Arcana Institute, Cracow, Poland, Novo Nordisk Pharma Poland, Warsaw, Poland
1 1 1 1 1 1 1 1 1 2 2
1 2
Insulin detemir PacketPublic selling
price (VAT
included) [PLN]
Reimbursement[PLN]
Patient’s co-payment
[PLN]
Reimbursementper
1 i.u. [PLN]
Levemir 5 wkł. 3ml 271,01 267,81 3,20 0,18
Type 1 and type 2 diabetespatients treated with IIT
Proportion of patients withepisodes of severe
hypoglycaemia *
Proportion of patientstreated with IIT,
receiving NPH insulinTarget population
65 800 0,089 95% 65 800 × 95% × 8,9% = about 5,6thousand patients
Total annual cost [PLN] IDet NPH
Type 1 diabetes
Insulin detemir/NPH 1 903,74 792,82
Short-/ rapid-acting insulin 828,42 592,85
Total 2 732,16 1 385,67
Type 2 diabetes (intensive insulin therapy)
Insulin detemir/NPH 2 662,87 1 005,92
Short-/ rapid-acting insulin 1 325,69 782,13
Total 3 988,56 1 788,05
Type 2 diabetes (insulin + oral antidiabetes drugs)
Insulin detemir/NPH 3 303,17 1 114,11
Oral antidiabetes drugs 327,38 327,38
Total 3 630,55 1 441,49
